(Q50860871)

24 March 2018

title

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). (English)

1 reference

24 March 2018

Erratum: Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

1 reference

corrigendum / erratum

1 reference

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/LEU.2013.299

author

Oliver Hantschel

6

1 reference

24 March 2018

author name string

T Zhou

1

1 reference

24 March 2018

S Georgeon

2

1 reference

24 March 2018

R Moser

3

1 reference

24 March 2018

D J Moore

4

1 reference

24 March 2018

A Caflisch

5

1 reference

24 March 2018

publication date

4 July 2013

1 reference

24 March 2018

published in

Leukemia

1 reference

24 March 2018

volume

28

1 reference

24 March 2018

issue

2

1 reference

24 March 2018

page(s)

404-407

1 reference

24 March 2018

https://scigraph.springernature.com/pub.10.1038/leu.2013.205

exact match

0 references

cites work

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.205

The genetic basis of myeloproliferative disorders

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23823659

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

JAK2 inhibitors and their impact in myeloproliferative neoplasms

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23823659

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.205

1 reference

24 March 2018

1 reference

24 March 2018